DCM Advisors LLC Buys 10,920 Shares of CVS Health Co. (NYSE:CVS)

DCM Advisors LLC grew its stake in CVS Health Co. (NYSE:CVS - Free Report) by 15.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 81,530 shares of the pharmacy operator's stock after acquiring an additional 10,920 shares during the quarter. CVS Health accounts for 1.6% of DCM Advisors LLC's holdings, making the stock its 21st biggest position. DCM Advisors LLC's holdings in CVS Health were worth $3,435,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

• MarketBeat Week in Review – 05/12 - 05/16

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Orion Capital Management LLC bought a new stake in CVS Health during the 4th quarter worth approximately $54,000. McIlrath & Eck LLC increased its stake in CVS Health by 32.6% during the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after purchasing an additional 174 shares in the last quarter. Novem Group bought a new stake in CVS Health during the 4th quarter worth approximately $562,000. NCM Capital Management LLC increased its stake in CVS Health by 184.2% during the 4th quarter. NCM Capital Management LLC now owns 11,225 shares of the pharmacy operator's stock worth $504,000 after purchasing an additional 7,276 shares in the last quarter. Finally, White Knight Strategic Wealth Advisors LLC increased its stake in CVS Health by 176.0% during the 4th quarter. White Knight Strategic Wealth Advisors LLC now owns 15,740 shares of the pharmacy operator's stock worth $707,000 after purchasing an additional 10,038 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

Insider Buying and Selling at CVS Health

In other CVS Health news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company's stock, valued at $556,941.90. This trade represents a 47.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.22% of the company's stock.

Analyst Ratings Changes

• Is It Time to Buy the Dip in Novo Nordisk Stock?

A number of analysts recently issued reports on the company. Morgan Stanley reissued an "overweight" rating on shares of CVS Health in a research note on Tuesday, April 15th. Piper Sandler increased their target price on CVS Health from $72.00 to $74.00 and gave the stock an "overweight" rating in a research note on Friday, March 21st. UBS Group upped their price target on CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a research report on Friday, May 2nd. Mizuho upped their price target on CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Finally, Wolfe Research upped their price target on CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $74.94.

View Our Latest Analysis on CVS

CVS Health Trading Down 2.5%

• Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

NYSE CVS opened at $62.13 on Thursday. The company has a market cap of $78.59 billion, a PE ratio of 16.97, a PEG ratio of 0.98 and a beta of 0.60. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $72.51. The stock has a 50 day moving average of $66.41 and a 200-day moving average of $59.34.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same quarter in the prior year, the firm posted $1.31 EPS. The firm's revenue for the quarter was up 7.0% compared to the same quarter last year. On average, equities research analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.28%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health's dividend payout ratio is 63.48%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Featured Stories

• Five stocks we like better than CVS Health
• What is the Australian Securities Exchange (ASX)
• $30B AI Opportunity: Will It Power Meta’s Next Surge?
• 3 Warren Buffett Stocks to Buy Now
• Microsoft Could Rally as EU Antitrust Case Nears Resolution
• Expert Stock Trading Psychology Tips
• Intel Refocuses: NEX Sale and Foundry Pivot Signal New Era

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CVS Health Right Now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here